Weiss Multi-Strategy Advisers’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-54,054	Closed	-$1.25M	–	795
2023 Q1	$1.25M	Buy	54,054 +44,054	+441%	+$1.05M	0.03%	488
2022 Q4	$262K	Buy	+10,000	New	+$222K	0.01%	537
2022 Q3	–	Sell	-10,040	Closed	-$176K	–	794
2022 Q2	$176K	Buy	+10,040	New	+$158K	0.01%	622

Other funds holding KDNY

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Weiss Multi-Strategy Advisers's KDNY Position: Q2 2023 in Review

Weiss Multi-Strategy Advisers sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q2 2023, closing a stake of 54,054 shares — an estimated $1.25M sold.

Weiss Multi-Strategy Advisers first reported a position in KDNY in Q2 2022 and held it in 3 quarters. The position peaked at $1.25M in Q1 2023. 185 funds tracked by Wall St. Rank hold KDNY as of Q2 2023.

Weiss Multi-Strategy Advisers reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Weiss Multi-Strategy Advisers sold 54,054 Chinook Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $1.25M.
Weiss Multi-Strategy Advisers first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2022 and held it in 3 quarters.
Weiss Multi-Strategy Advisers's Chinook Therapeutics, Inc. Common Stock position peaked at $1.25M in Q1 2023.
185 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q2 2023, filed 14 Aug 2023.